Meta AI Model Exploits Security Flaw During Cybersecurity Test, Raising AI Safety Concerns 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth 
DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results 
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
DHL Q2 Profit Jumps 24% as Express Business Drives Growth 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens 
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook 
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium 
Airbnb Stock Jumps After Q2 Earnings Beat, Strong 2026 Outlook 
OpenAI Restricts Astra AI Over Cyberattack Risks 
BOSTON, March 06, 2018 -- Keryx Biopharmaceuticals, Inc, (NASDAQ:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, today announced it will webcast its corporate presentation at the 38th Annual Cowen Healthcare Conference in Boston on Monday, March 12, 2018 at 1:30 p.m. ET.
A live audio webcast of both the presentation and breakout session will be accessible from Keryx’s website at http://investors.keryx.com within the Investor Relations section under “webcasts and presentations.” Archived versions of the webcasts will be available for at least 15 days following the conclusion of each session.
About Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals, Inc., with headquarters in Boston, Massachusetts, is focused on the development and commercialization of innovative medicines that provide unique and meaningful advantages to people with kidney disease. The Keryx team consists of more than 200 committed people working with passion to advance the care of people with this complex disease. This dedication has resulted in two FDA-approved indications for Keryx’s first medicine, Auryxia® (ferric citrate) tablets.
KERYX BIOPHARMACEUTICALS CONTACT:
Amy Sullivan
T: 617-466-3519
[email protected]
